门诊恶化心力衰竭:创新的去充血策略和健康公平的影响。

IF 4.5 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Rami Halaseh, Grace K Sun, Ankeet S Bhatt, Alex J Chang, Jana Svetlichnaya, Sirtaz Adatya, Marat Fudim, Stephen J Greene, Daniel R Bensimhon, Eric D Adler, Tamas Alexy, Jan Biegus, Andrew J Sauer, Peter S Pang, Sean P Collins, Ambarish Pandey, Javed Butler, Andrew P Ambrosy
{"title":"门诊恶化心力衰竭:创新的去充血策略和健康公平的影响。","authors":"Rami Halaseh, Grace K Sun, Ankeet S Bhatt, Alex J Chang, Jana Svetlichnaya, Sirtaz Adatya, Marat Fudim, Stephen J Greene, Daniel R Bensimhon, Eric D Adler, Tamas Alexy, Jan Biegus, Andrew J Sauer, Peter S Pang, Sean P Collins, Ambarish Pandey, Javed Butler, Andrew P Ambrosy","doi":"10.1007/s10741-025-10509-y","DOIUrl":null,"url":null,"abstract":"<p><p>Worsening heart failure (WHF) is a major clinical and economic challenge, contributing to high rates of hospitalization and significant healthcare costs. While WHF has traditionally been managed through hospitalization, recent approaches are shifting toward outpatient care to maximize patient time spent at home and optimize allocation of hospital resources. Emerging treatments like subcutaneous furosemide and intranasal bumetanide offer promising alternatives for safe, well-tolerated, and effective diuresis outside the hospital. However, these novel strategies face several challenges, including the need for clinician/staff training, patient education, logistical difficulties, and a lack of evidence in diverse populations. To ensure equitable management, it is also essential to address healthcare disparities, particularly in socioeconomically disadvantaged and rural populations. While these new treatments have the potential to improve care delivery, additional research is necessary to assess their comparative effectiveness and overcome current limitations fully.</p>","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Outpatient worsening heart failure: innovative decongestion strategies and health equity implications.\",\"authors\":\"Rami Halaseh, Grace K Sun, Ankeet S Bhatt, Alex J Chang, Jana Svetlichnaya, Sirtaz Adatya, Marat Fudim, Stephen J Greene, Daniel R Bensimhon, Eric D Adler, Tamas Alexy, Jan Biegus, Andrew J Sauer, Peter S Pang, Sean P Collins, Ambarish Pandey, Javed Butler, Andrew P Ambrosy\",\"doi\":\"10.1007/s10741-025-10509-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Worsening heart failure (WHF) is a major clinical and economic challenge, contributing to high rates of hospitalization and significant healthcare costs. While WHF has traditionally been managed through hospitalization, recent approaches are shifting toward outpatient care to maximize patient time spent at home and optimize allocation of hospital resources. Emerging treatments like subcutaneous furosemide and intranasal bumetanide offer promising alternatives for safe, well-tolerated, and effective diuresis outside the hospital. However, these novel strategies face several challenges, including the need for clinician/staff training, patient education, logistical difficulties, and a lack of evidence in diverse populations. To ensure equitable management, it is also essential to address healthcare disparities, particularly in socioeconomically disadvantaged and rural populations. While these new treatments have the potential to improve care delivery, additional research is necessary to assess their comparative effectiveness and overcome current limitations fully.</p>\",\"PeriodicalId\":12950,\"journal\":{\"name\":\"Heart Failure Reviews\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2025-04-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Heart Failure Reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10741-025-10509-y\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart Failure Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10741-025-10509-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

心力衰竭(WHF)恶化是一个重大的临床和经济挑战,导致高住院率和巨大的医疗保健费用。虽然WHF传统上是通过住院治疗来管理的,但最近的方法正在转向门诊治疗,以最大限度地延长患者在家的时间并优化医院资源的分配。新兴的治疗方法,如皮下速尿和鼻内布美他尼,为安全、耐受性良好和有效的院外利尿提供了有希望的替代方法。然而,这些新策略面临着一些挑战,包括需要临床医生/工作人员培训、患者教育、后勤困难以及缺乏不同人群的证据。为确保公平管理,还必须解决保健差距问题,特别是在社会经济上处于不利地位的人口和农村人口中。虽然这些新的治疗方法有可能改善护理服务,但还需要进一步的研究来评估它们的相对有效性,并充分克服目前的局限性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Outpatient worsening heart failure: innovative decongestion strategies and health equity implications.

Worsening heart failure (WHF) is a major clinical and economic challenge, contributing to high rates of hospitalization and significant healthcare costs. While WHF has traditionally been managed through hospitalization, recent approaches are shifting toward outpatient care to maximize patient time spent at home and optimize allocation of hospital resources. Emerging treatments like subcutaneous furosemide and intranasal bumetanide offer promising alternatives for safe, well-tolerated, and effective diuresis outside the hospital. However, these novel strategies face several challenges, including the need for clinician/staff training, patient education, logistical difficulties, and a lack of evidence in diverse populations. To ensure equitable management, it is also essential to address healthcare disparities, particularly in socioeconomically disadvantaged and rural populations. While these new treatments have the potential to improve care delivery, additional research is necessary to assess their comparative effectiveness and overcome current limitations fully.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Heart Failure Reviews
Heart Failure Reviews 医学-心血管系统
CiteScore
10.40
自引率
2.20%
发文量
90
审稿时长
6-12 weeks
期刊介绍: Heart Failure Reviews is an international journal which develops links between basic scientists and clinical investigators, creating a unique, interdisciplinary dialogue focused on heart failure, its pathogenesis and treatment. The journal accordingly publishes papers in both basic and clinical research fields. Topics covered include clinical and surgical approaches to therapy, basic pharmacology, biochemistry, molecular biology, pathology, and electrophysiology. The reviews are comprehensive, expanding the reader''s knowledge base and awareness of current research and new findings in this rapidly growing field of cardiovascular medicine. All reviews are thoroughly peer-reviewed before publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信